Women choose contraceptives like Depo-Provera trusting they are safe for long-term use. A subsequent diagnosis of a brain tumor shatters that trust, leaving families facing a difficult medical and emotional journey.
As the science linking this widely used contraceptive to meningiomas grows stronger, a nationwide legal effort is underway to hold the manufacturer accountable.
The most significant event in the Depo-Provera MDL is a legal battle over a concept called federal preemption. Pfizer is attempting to dismiss the entire litigation by arguing that federal law prevents plaintiffs from bringing their claims.
Pfizer claims it is shielded from liability because the FDA rejected a weak label change the company proposed in 2024. The manufacturer argues this rejection legally barred them from adding a stronger warning about brain tumors. If the court accepts this defense, it could end many of the cases before they begin.
Plaintiffs’ attorneys argue that Pfizer’s defense does not meet the high legal standard for preemption. The FDA’s rejection of a vague and scientifically weak proposal does not mean it prohibited a clear, specific, and accurate warning.
The law does not protect a company from liability when it offers a token gesture and then retreats from its duty to warn. The court will hear arguments on this critical motion on September 29, 2025.
The fight for justice is not confined to one courtroom. While a federal court coordinates hundreds of cases, many plaintiffs also pursue claims in state courts, creating multiple avenues for accountability.
Over 550 lawsuits have been consolidated into an MDL in the Northern District of Florida. An MDL is not a class action; each plaintiff’s case remains individual. The process streamlines pretrial activities like evidence gathering to make the litigation more efficient for everyone involved.
Many women are choosing to file their Depo-Provera lawsuits in state courts, particularly in New York, Delaware, and Pennsylvania. This strategy creates a parallel track of litigation that prevents Pfizer from focusing all of its resources on a single defense.
These lawsuits are built on a growing body of scientific evidence linking Depo-Provera’s active ingredient to an increased risk of meningioma brain tumors. Recent studies have made this connection even clearer.
A 2025 study from the University of British Columbia provided powerful new evidence. Researchers found that women who used Depo-Provera for more than one year had a 3.55-fold increased risk of developing a meningioma compared to women using other contraceptives. This study corrected for limitations in earlier research, making its conclusions more robust.
This new research provides a stronger scientific foundation for the claims against Pfizer. The study’s key contributions help build a more compelling case for manufacturer accountability.
This type of independent, peer-reviewed research is crucial in litigation. It provides the objective evidence needed to show a jury that the risks were real and should have been disclosed to patients.
Plaintiffs are also raising questions about the 150 mg dose of Depo-Provera. A lower-dose alternative, Depo-SubQ Provera 104, provides the same contraceptive effect with significantly less of the synthetic hormone.
Discovery will examine whether Pfizer knew this unnecessarily high dosage elevated the risk of brain tumors but chose not to promote the safer alternative.
The judge overseeing the federal MDL, M. Casey Rodgers, is known for moving cases along quickly. She has implemented several orders to keep the litigation on schedule and ensure all parties meet their obligations.
All plaintiffs in the MDL must complete a detailed questionnaire and provide medical records proving their use of Depo-Provera and their subsequent meningioma diagnosis.
The court has set firm deadlines for these submissions, and failure to comply can put a person’s case at risk of dismissal.
The judge has also questioned law firms about the number of potential cases they are investigating but have not yet filed. This reflects a tension in mass torts between protecting clients from a potentially negative early ruling and providing the court with a clear picture of the litigation’s true scope.
Most states have a “discovery rule,” which means the clock for filing a lawsuit does not start until a person knows, or reasonably should have known, that their injury was connected to the defendant’s product. Since the link between Depo-Provera and meningiomas only became widely known through recent studies, most women are still within their time limit to file.
You will need to provide records that confirm you were administered Depo-Provera and records that confirm your meningioma diagnosis. This can include pharmacy records, clinic notes, doctor’s reports, and surgical or pathology reports. Brain injury attorneys can help you gather this documentation.
Lawsuits are often filed where a defendant company is incorporated or has a major place of business. Since Pfizer and its related entities have corporate ties to these states, plaintiffs from anywhere in the country can legally file their claims there, often in courts known for efficiently managing complex litigation.
In an MDL, the judge and attorneys may select a small number of representative cases to go to trial first. These are called bellwether trials. The outcomes of these initial trials help both sides understand the strengths and weaknesses of their arguments and often influence settlement negotiations for all remaining cases.
If you or a loved one used Depo-Provera for at least one year and were later diagnosed with a meningioma brain tumor, you may be able to seek justice. The personal injury attorneys at Stark & Stark are reviewing these cases and fighting to hold pharmaceutical companies accountable.
Contact us at 800.535.3425 for a free, no-obligation consultation to discuss your case.
Stark & Stark Attorneys Recognized as New Jersey “Super Lawyers” and “Rising Stars” in 2026
Stark & Stark is pleased to announce that 15 of its attorneys have been selected for inclusion in the list of 2026 New Jersey Super Lawyers,...Bruce Stern, Esq. Secures $1,000,000 Settlement in Motor Vehicle Collision Case
Bruce Stern, Esq. recently secured a $1,000,000 settlement in a motor vehicle collision case.* “This case highlights how quickly things can go...Deborah Dunn, Esq. Elected to Board of Directors for Angel Flight East
Stark & Stark is pleased to announce that Deborah Dunn, Esq., Shareholder and Civil Trial Attorney, has been elected to the Board of Directors...Michael Jordan, Esq. Joins the Board of the Lawrence Township Community Foundation
It is our pleasure to announce that Michael Jordan, Esq. has joined the board of the Lawrence Township Community Foundation, an organization...Joseph Lemkin, Esq. Named to ROI-NJ Influencers: Power List 2026 – Law
Stark & Stark is proud to share that Joseph Lemkin, Esq., Shareholder, has been named to the 2026 Influencers: Power List in the Law category...Joseph Cullen, Esq. and Nicole Durso, Esq. Secure $2,000,000 Settlement in Personal Injury Matter
Joseph Cullen, Esq. and Nicole Durso, Esq. recently secured a $2,000,000 settlement in a personal injury matter involving a pedestrian who was struck...James Creegan, Esq. Appointed to Board of The 200 Club of Mercer County
It is our pleasure to announce that James Creegan, Esq. has been appointed to the Board of Directors of The 200 Club of Mercer County, an...
